Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Optimeos Life Sciences
AddedFeb 19, 2024
UpdatedJun 18, 2026
Optimeos Life Sciences

Optimeos Life Sciences

Angel

Optimeos Life Sciences: Pioneering sustained, nanoparticle-enabled biologics delivery for advanced care.

HQ
Princeton, NJ, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Optimeos Life Sciences is dedicated to pioneering a novel nanoparticle-enabled approach for the sustained delivery of biologics, aiming to advance medical treatment and patient care. The company focuses on developing a transformative platform for the intracellular delivery of RNA and DNA, addressing the limitations of first-generation lipid nanoparticle technology. Their innovative solutions target the growing market of therapeutic RNAs, positioning them at the forefront of next-generation medical treatments.

Optimeos Life Sciences has made significant strides in enhancing the tolerability, effectiveness, and longevity of RNA payloads through their advanced nanoparticle platform. This breakthrough technology has the potential to revolutionize the delivery and efficacy of RNA and DNA medicines, positioning the company as a key player in the biopharmaceutical industry. Their impact is marked by their commitment to improving patient outcomes and advancing the field of biologics delivery.

Optimeos Life Sciences - Quick Facts

When was Optimeos Life Sciences founded?

Optimeos Life Sciences was founded in 2016.

Where is Optimeos Life Sciences' headquarters located?

Optimeos Life Sciences' headquarters is located in Princeton, NJ, US.

When was Optimeos Life Sciences' last funding round?

Optimeos Life Sciences' most recent funding round was for $50k (USD) in February 2023.

How much has Optimeos Life Sciences raised to-date?

As of Feb 16, 2023, Optimeos Life Sciences has raised a total of $631k (USD).

How many employees does Optimeos Life Sciences have?

Optimeos Life Sciences has 5 employees as of Feb 5, 2024.

Optimeos Life Sciences - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Nanotechnology
Geographic Exposure
  • Global
Model
  • Platform
Customer
  • Enterprise
Main Product
  • Biologics Delivery
Tags
  • Biotech
  • Consulting
  • Healthcare
  • Healthtech
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified